Novavax Inc (NVAX)

0.83
NASDAQ : Health Care
Prev Close 0.82
Day Low/High 0.82 / 0.84
52 Wk Low/High 0.73 / 8.49
Avg Volume 6.30M
Exchange NASDAQ
Shares Outstanding 271.95M
Market Cap 223.00M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Under $10 Could Ignite Soon

These 5 Stocks Under $10 Could Ignite Soon

Here's a technical look at how to trade several under-$10 stocks that could break out soon.

Biotech Premarket Movers: Cempra, Novavax, Ionis

Biotech Premarket Movers: Cempra, Novavax, Ionis

Cempra, Novavax and Ionis Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo

Amicus Therapeutics, Nantkwest and Organovo are among the premarket biotech movers on Tuesday.

5 Stocks Setting Up for Big Breakouts

5 Stocks Setting Up for Big Breakouts

Here's how to rake in the gains.

Commit To Purchase Novavax At $1, Earn 25% Using Options

Commit To Purchase Novavax At $1, Earn 25% Using Options

Investors eyeing a purchase of Novavax, Inc. stock, but tentative about paying the going market price of $1.32/share, might benefit from considering selling puts among the alternative strategies at their disposal.

UPDATE -- Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016

UPDATE -- Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016

Financial results conference call will include Investor and Analyst webcast presentation

Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016

Novavax To Host Conference Call To Discuss Third Quarter Financial Results On November 9, 2016

Financial results conference call will include Investor and Analyst webcast presentation

5 Stocks Under $10 That Could Make You a Lot of Money

5 Stocks Under $10 That Could Make You a Lot of Money

These stocks trading for less than $10 a share are within range of triggering big breakout trades. Here's how to trade them from here.

These 7 Stocks Are Trading on Big Volume -- Here's What to Do With Them Now

These 7 Stocks Are Trading on Big Volume -- Here's What to Do With Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid

5 Big-Volume Stocks to Add to Your Buy List -- Plus 2 to Avoid

Here's a technical look at how to trade some of the most active stocks on the market right now.

Twitter, Intel, Starbucks: Doug Kass' Views

Twitter, Intel, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on what goes on his best ideas list and what's still moving down.

Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass

Underlying Risks in Speculative Biotechs; Trump Speaks, Bonds Slide : Best of Kass

In highlights from this week's trading diary and posts, Kass tells us about underlying risks in speculative biotechs and how Donald Trump's voice makes bonds slide.

Novavax's Chart Looked Good, Until It Didn't

Novavax's Chart Looked Good, Until It Didn't

Things were looking up and then today happened.

Look to Costamare for Value in Shipping

Look to Costamare for Value in Shipping

It's safe to say these guys know what they are doing.

Novavax's Steep Decline Underlines Small-Cap Biotech Risk

But we remain committed to our position in TherapeuticsMD.

Novavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades

Novavax (NVAX) Stock Tumbles on Vaccine Trial Failure, Ratings Downgrades

Novavax (NVAX) stock rating was reduced at several firms this morning after the company's RSV-F vaccine didn't achieve its primary and secondary endpoints in a clinical trial.

Analysts' Actions -- Citigroup, Comerica, Novavax, PepsiCo and More

Analysts' Actions -- Citigroup, Comerica, Novavax, PepsiCo and More

Here are Friday's top research calls, including downgrades for Citigroup and Novavax, an upgrade Comerica and new coverage of PepsiCo.